The drug Enhertu, already available in 19 European countries, is denied to over 1000 patients with advanced breast cancer in the UK due to NICE's funding rejection.
It's deeply unjust that patients are in a stand-off between NICE and pharmaceutical companies. Access to life-extending treatment is crucial for those diagnosed terminally.
I want to stay alive, I want to keep living. I'm really, really annoyed that NICE doesn't think my life is important enough to extend.
Enhertu could give patients an average of six additional months to live. NICE's decision impacts many, preventing them from accessing potentially life-saving treatment.
Collection
[
|
...
]